Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Bone Marrow T Cells Exhibit Conditional Preparedness Against Cancer

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.

10 Aug 2026

Modulating T Cell Exhaustion Offers Novel Therapeutic Pathways in Transplantation

A comprehensive new review examines the complex role of T cell exhaustion in organ transplantation, highlighting how this dysfunctional immune state can both promote graft tolerance and create vulnerabilities to infection and malignancy.

7 Aug 2026

Tireless Stem Cells Drive Continuous Renewal Across High Friction Human Intestines

Digestion is hard on the cells that line the human gut, and they are constantly being shed and replaced. This renewal is driven by a population of tireless stem cells. These stem cells can both replace the various types of intestinal cells that have been lost as well as renew themselves.

6 Aug 2026

Indiana University Evaluates Nabsys Breakthrough Genome Mapping Technology

Nabsys 2.0, LLC ("Nabsys"), a pioneer in electronic genome mapping (EGM) technology, today announced a multi-year research collaboration with the Indiana University School of Medicine to develop and evaluate Electronic Genome Mapping applications for hematologic malignancies.

3 Aug 2026

Study Uncovers Two Distinct Embryonic Macrophage Populations with Different Repair Abilities

In leukemia's most aggressive forms, the blood cell factories in our bone marrow falter. Instead of dividing and multiplying at their usual prolific pace, generating hundreds of billions of new cells daily, some precursor cells stall out at an immature stage.

27 Jul 2026

Novel T Cell Immune Path Targets Aggressive Acute Myeloid Leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

16 Jul 2026

Enigmatic MLL4 Protein Drives Leukemia While Suppressing Solid Tumors

The epigenetic modifier MLL4 has an unassuming name-the 4, for instance, indicates it's just one in a family of such modifiers.

14 Jul 2026

Antibody-Based Strategy Makes Stem Cell Transplants Safer

Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative approaches for blood diseases such as sickle cell disease, b-thalassemia, immune deficiencies, and some blood cancers.

9 Jul 2026

Eradicating Lingering Cancer Cells Prevents Relapse in B Cell Leukemia

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

9 Jul 2026

Antibody Drug Conjugate Treatment Destroys Hidden B Cell Leukemia

By using the antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat B-cell acute lymphoblastic leukemia (ALL) patients, researchers at The University of Texas MD Anderson Cancer Center were able to eliminate measurable residual disease (MRD), a crucial step in enhancing long-term survival outcomes.

8 Jul 2026

New Study Explains How Blood Cancer Cells Invade the Lungs

Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.

30 Jun 2026

Indiana University Study Identifies New Pathway to Combat Leukemia

Indiana University School of Medicine cancer researchers have identified a potential way to use existing, accessible drugs to combat juvenile myelomonocytic leukemia (JMML) by targeting a specific inflammatory pathway.

19 Jun 2026

Low-Oxygen Environments Enhance Engraftment and Function of Transplanted Stem Cells

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have found that human hematopoietic stem cells are highly sensitive to oxygen, which can dictate how the cells grow and function.

19 May 2026

CIPHER-seq Reveals RNA and Protein Activity in Immune Cells

A new single-cell technology is giving scientists their clearest view yet of immune cell behavior-capturing not just genetic intent but real-time activity.

9 Apr 2026

ASHOP Platform Unifies Multi-Omics Data for Blood Cancer Insights

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia Laboratory have developed a data-sharing platform that unites genomics, gene expression and clinical information from nearly 6,000 patients with blood cancers.

7 Apr 2026

Nonviral Nanoparticles Show Promise for Safer Gene Delivery Methods

In a demonstration that helps pave the way for gene therapies with fewer side effects, several human cell types were genetically modified with protein nanoparticles designed at University of Michigan Engineering and Michigan Medicine.

1 Apr 2026

Novel Immunotherapy Disrupts the Protective Tumor Microenvironment Ecosystem

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two main reasons: tumor cells often don't share one consistent surface target, and many solid tumors are protected by a dense network of scar tissue and immune-suppressive cells that blocks T cells.

31 Mar 2026

New Mechanism Links Mitochondria Dysfunction to T Cell Exhaustion

The immune system's killer T cells do a commendable job of detecting and destroying cancer cells. But the harsh environment at the heart of tumors often saps them of their vitality, pushing them into a state of permanent lassitude called "terminal exhaustion."

23 Mar 2026

Tumor Environment Constrains Cellular Signal Carrying Vesicles

A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells that are embedded in tissue.

12 Feb 2026

Novel RNA Molecule Preserves Cell Structure, Impacts Cancer Survival

In a recent study published in the Proceedings of the National Academy of Sciences (PNAS), researchers at the Texas A&M University Health Science Center (Texas A&M Health) identify a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus (a dense region of the cell containing a subset of crucial genetic material).

3 Feb 2026